Details of the Drug

General Information of Drug (ID: DMWLC57)

• Drug Name: Brentuximab vedotin
• Synonyms: Adcetris (TN)

Indication

Disease Entry	ICD 11	Status	REF
Hodgkin lymphoma	2B30	Approved	[1], [2], [3]

• Drug Type: Monoclonal antibody
• ADMET Property:
  Elimination: About 24% of the total MMAE ingested as part of the ADC during an ADCETRIS infusion was recovered in both urine and feces over a 7-day time frame [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 4 - 6 days [5]
  Metabolism: The drug is metabolized via oxidation by CYP3A4/5 [5]
• Cross-matching ID:
  DrugBank ID: DB08870
  TTD ID: D03TIS
  INTEDE ID: DR0225

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lymphocyte activation antigen CD30 (TNFRSF8)	TT2GM5R	TNR8_HUMAN	Modulator	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[7]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Brentuximab vedotin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[27]
Sarecycline	DMLZNIQ	Moderate	Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Sarecycline .	Acne vulgaris [ED80]	[28]
Tagraxofusp	DM9HQ5U	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Tagraxofusp.	Acute myeloid leukaemia [2A60]	[28]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Gilteritinib.	Acute myeloid leukaemia [2A60]	[28]
Inotersen	DMJ93CT	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Inotersen.	Amyloidosis [5D00]	[28]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[29]
Troleandomycin	DMUZNIG	Moderate	Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Troleandomycin.	Bacterial infection [1A00-1C4Z]	[30]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[31]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[32]
Eribulin	DM1DX4Q	Moderate	Increased risk of peripheral neuropathy by the combination of Brentuximab vedotin and Eribulin.	Breast cancer [2C60-2C6Y]	[33]
HKI-272	DM6QOVN	Moderate	Decreased clearance of Brentuximab vedotin due to the transporter inhibition by HKI-272.	Breast cancer [2C60-2C6Y]	[28]
LY2835219	DM93VBZ	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and LY2835219.	Breast cancer [2C60-2C6Y]	[28]
Tucatinib	DMBESUA	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Tucatinib.	Breast cancer [2C60-2C6Y]	[30]
Alpelisib	DMEXMYK	Moderate	Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Alpelisib.	Breast cancer [2C60-2C6Y]	[28]
Fenofibric acid	DMGO2MC	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Fenofibric acid.	Cardiovascular disease [BA00-BE2Z]	[28]
Macitentan	DMP79A1	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Macitentan.	Cardiovascular disease [BA00-BE2Z]	[28]
Regorafenib	DMHSY1I	Moderate	Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Regorafenib.	Colorectal cancer [2B91]	[30]
Intedanib	DMSTA36	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Intedanib.	Colorectal cancer [2B91]	[28]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Cannabidiol.	Epileptic encephalopathy [8A62]	[34]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Brentuximab vedotin caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[34]
Daclatasvir	DMSFK9V	Moderate	Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Daclatasvir.	Hepatitis virus infection [1E50-1E51]	[28]
177Lu-DOTATATE	DMT8GVU	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[28]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Brentuximab vedotin caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[34]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[35]
Givosiran	DM5PFIJ	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[28]
Brigatinib	DM7W94S	Moderate	Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Brigatinib.	Lung cancer [2C25]	[30]
Lurbinectedin	DMEFRTZ	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Lurbinectedin.	Lung cancer [2C25]	[28]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Brentuximab vedotin caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[34]
Alectinib	DMP1I6Y	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Alectinib.	Lung cancer [2C25]	[28]
BIBW 2992	DMTKD7Q	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and BIBW 2992.	Lung cancer [2C25]	[28]
Pralsetinib	DMWU0I2	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Pralsetinib.	Lung cancer [2C25]	[28]
Capmatinib	DMYCXKL	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Capmatinib.	Lung cancer [2C25]	[30]
Selpercatinib	DMZR15V	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Selpercatinib.	Lung cancer [2C25]	[28]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[28]
IPI-145	DMWA24P	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and IPI-145.	Mature B-cell leukaemia [2A82]	[28]
Blinatumomab	DMGECIJ	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Blinatumomab.	Mature B-cell lymphoma [2A85]	[28]
Ponatinib	DMYGJQO	Moderate	Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Ponatinib.	Mature B-cell lymphoma [2A85]	[30]
Arry-162	DM1P6FR	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Arry-162.	Melanoma [2C30]	[28]
Vemurafenib	DM62UG5	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Vemurafenib.	Melanoma [2C30]	[30]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[36]
Carfilzomib	DM48K0X	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Carfilzomib.	Multiple myeloma [2A83]	[37]
Tecfidera	DM2OVDT	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Tecfidera.	Multiple sclerosis [8A40]	[28]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Brentuximab vedotin and Siponimod.	Multiple sclerosis [8A40]	[38]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Brentuximab vedotin and Ocrelizumab.	Multiple sclerosis [8A40]	[39]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Brentuximab vedotin and Ozanimod.	Multiple sclerosis [8A40]	[34]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[28]
Entrectinib	DMMPTLH	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Entrectinib.	Non-small cell lung cancer [2C25]	[28]
Istradefylline	DM20VSK	Moderate	Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Istradefylline.	Parkinsonism [8A00]	[28]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Brentuximab vedotin caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[40]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Brentuximab vedotin caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[41]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Brentuximab vedotin caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[42]
Sarilumab	DMOGNXY	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Sarilumab.	Rheumatoid arthritis [FA20]	[28]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Brentuximab vedotin when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[43]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Brentuximab vedotin caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[34]
Larotrectinib	DM26CQR	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Larotrectinib.	Solid tumour/cancer [2A00-2F9Z]	[28]
LEE011	DMMX75K	Moderate	Decreased clearance of Brentuximab vedotin due to the transporter inhibition by LEE011.	Solid tumour/cancer [2A00-2F9Z]	[30]
Pomalidomide	DMTGBAX	Moderate	Increased risk of peripheral neuropathy by the combination of Brentuximab vedotin and Pomalidomide.	Systemic sclerosis [4A42]	[33]
Fostamatinib	DM6AUHV	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Fostamatinib.	Thrombocytopenia [3B64]	[28]
Lenvatinib	DMB1IU4	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Lenvatinib.	Thyroid cancer [2D10]	[28]
Cabozantinib	DMIYDT4	Moderate	Decreased clearance of Brentuximab vedotin due to the transporter inhibition by Cabozantinib.	Thyroid cancer [2D10]	[28]
Elagolix	DMB2C0E	Moderate	Increased risk of hepatotoxicity by the combination of Brentuximab vedotin and Elagolix.	Uterine fibroid [2E86]	[28]
Secnidazole	DMJ18YL	Moderate	Increased risk of peripheral neuropathy by the combination of Brentuximab vedotin and Secnidazole.	Vaginal discharge [MF3A]	[33]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6772).
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] ClinicalTrials.gov (NCT01990534) A Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma. U.S. National Institutes of Health.
• [4] An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
• [5] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [6] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [7] Brentuximab vedotin.
• [8] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [9] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [10] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [11] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [12] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [13] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [14] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [15] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [16] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [17] Clinical pipeline report, company report or official report of Affimed Therapeutics.
• [18] Utilizing CD30 expression as a rational target for therapy of lymphoma. J Hematol Oncol. 2012; 5(Suppl 1): A2.
• [19] The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002 Jul 1;62(13):3736-42.
• [20] ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
• [21] ClinicalTrials.gov (NCT03125577) Combination CAR-T Cell Therapy Targeting Hematological Malignancies
• [22] ClinicalTrials.gov (NCT02274584) CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)
• [23] ClinicalTrials.gov (NCT02259556) CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas
• [24] ClinicalTrials.gov (NCT02663297) Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
• [25] ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
• [26] ClinicalTrials.gov (NCT02958410) A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies
• [27] European Medicines Agency "Summary on compassionate use. Remdesivir Gilead.".
• [28] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [29] Product Information. Hivid (zalcitabine). Roche Laboratories, Nutley, NJ.
• [30] Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
• [31] Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
• [32] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [33] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
• [34] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [35] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [36] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [37] Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
• [38] Cerner Multum, Inc. "Australian Product Information.".
• [39] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [40] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [41] Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
• [42] Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
• [43] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]